Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 9
Wegovy weight loss pill gets UK approval
The MHRA approved oral Wegovy (semaglutide 25 mg tablets) for weight management in adults on 11 June 2026, making it the first oral GLP-1 for obesity in the UK.
Optic neuropathy after semaglutide ramp-up
A 2026 case report describes atypical optic nerve damage behind the eye in a man on semaglutide 1 mg weekly, broadening the known spectrum of eye-related risks.
Biopsy-free MASH trials need longer runs
Ajmera and Loomba argue that NIT-based MASH trials must extend beyond 52 weeks and use composite non-invasive endpoints to capture fibrosis change.
CJC-1295/Ipamorelin 10 mg Blend Dosing
How to calculate the dose from a CJC-1295/ipamorelin 10 mg blend vial. Step-by-step reconstitution math and what the research actually supports.
CJC-1295 and Ipamorelin Hives Explained
Hives at old CJC-1295 and ipamorelin injection sites are usually mast-cell driven, not a true allergy. Here is what the literature says.
Dulaglutide in 2026: still relevant?
A narrative review argues dulaglutide still earns its place in cardiometabolic care despite tirzepatide and semaglutide gaining ground.
Dupuytren's contracture and peptides
Dupuytren's contracture surfaces in peptide forums alongside GLP-1 drugs. The biological overlap with fibrotic pathways is real. The direct evidence is not.
GLP-1 add-on doubled time in range: Ramadan
A 2026 CGM study found that adding semaglutide or tirzepatide to insulin doubled time in range during Ramadan fasting without raising hypoglycaemia risk.
GLP-1 drugs and knee replacement risk
A large retrospective study ties GLP-1 receptor agonist use to lower rates of knee replacement surgery for osteoarthritis.
GLP-1 drugs cut CV risk in type 2 diabetes
A 2026 network meta-analysis finds GLP-1 therapies reduce mortality and MACE in type 2 diabetes. Semaglutide and albiglutide rank highest.
GLP-1 drugs and hair loss: the data
Hair loss affects roughly 4% of GLP-1 receptor agonist users. The likely cause is rapid weight loss triggering telogen effluvium, not direct follicle damage.
GLP-1 drugs tied to lower heart risk in RA
A TriNetX cohort study found GLP-1 therapy halved heart failure and respiratory failure risk in non-diabetic adults with RA and obesity.